WO2015153864A3 - Methods for treating inflammatory conditions - Google Patents

Methods for treating inflammatory conditions Download PDF

Info

Publication number
WO2015153864A3
WO2015153864A3 PCT/US2015/024047 US2015024047W WO2015153864A3 WO 2015153864 A3 WO2015153864 A3 WO 2015153864A3 US 2015024047 W US2015024047 W US 2015024047W WO 2015153864 A3 WO2015153864 A3 WO 2015153864A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
methods
inflammatory
inflammatory conditions
detecting
Prior art date
Application number
PCT/US2015/024047
Other languages
French (fr)
Other versions
WO2015153864A2 (en
Inventor
Patricia T. HOPKINS
Original Assignee
Hopkins Patricia T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopkins Patricia T filed Critical Hopkins Patricia T
Publication of WO2015153864A2 publication Critical patent/WO2015153864A2/en
Publication of WO2015153864A3 publication Critical patent/WO2015153864A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention features methods of treating subjects for inflammatory conditions, such as mild traumatic brain injury (mTBI), osteoarthritis (OA), and fibromyalgia. The method may involve determining if the subject has such an inflammatory condition and administering an effective amount of a tetracycline compound (e.g., doxycycline) to the subject (e.g., a human). The invention also features methods for detecting an inflammatory condition in a subject by determining a level of an inflammatory biomarker, such as TGF-βΙ, in a biological sample (e.g., blood) obtained from the subject. Such methods can also be used as a companion diagnostic in combination with tetracycline treatment to assess treatment efficacy. The invention further features kits for detecting and treating such inflammatory conditions.
PCT/US2015/024047 2014-04-02 2015-04-02 Methods for treating inflammatory conditions WO2015153864A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461974118P 2014-04-02 2014-04-02
US61/974,118 2014-04-02
US201462074327P 2014-11-03 2014-11-03
US62/074,327 2014-11-03

Publications (2)

Publication Number Publication Date
WO2015153864A2 WO2015153864A2 (en) 2015-10-08
WO2015153864A3 true WO2015153864A3 (en) 2015-11-12

Family

ID=54241442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/024047 WO2015153864A2 (en) 2014-04-02 2015-04-02 Methods for treating inflammatory conditions

Country Status (1)

Country Link
WO (1) WO2015153864A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
JP2006505583A (en) 2002-10-25 2006-02-16 フォーミックス エルティーディー． Cosmetic and pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011039638A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
GB201603967D0 (en) 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
MX2020012139A (en) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Compositions and methods for treating rosacea and acne.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133586A2 (en) * 2006-05-08 2007-11-22 Tethys Bioscience, Inc. Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
WO2008046508A1 (en) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Tgfb2 as a biomarker, therapeutic and diagnostic target
US20080233206A1 (en) * 2007-03-23 2008-09-25 Molecular Research Center, Inc. Compositions and methods for anti-inflammatory treatments
US7611702B2 (en) * 2005-11-08 2009-11-03 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
US7691839B2 (en) * 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20130011849A1 (en) * 2007-01-31 2013-01-10 Henkin Robert I Methods for Detection of Biological Substances

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691839B2 (en) * 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US7611702B2 (en) * 2005-11-08 2009-11-03 Medarex, Inc. TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
WO2007133586A2 (en) * 2006-05-08 2007-11-22 Tethys Bioscience, Inc. Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
WO2008046508A1 (en) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Tgfb2 as a biomarker, therapeutic and diagnostic target
US20130011849A1 (en) * 2007-01-31 2013-01-10 Henkin Robert I Methods for Detection of Biological Substances
US20080233206A1 (en) * 2007-03-23 2008-09-25 Molecular Research Center, Inc. Compositions and methods for anti-inflammatory treatments

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"ACTAVIS 2014 Investor Meeting.", POWERPOINT PRESENTATION, 31 January 2014 (2014-01-31), pages 1 - 133, Retrieved from the Internet <URL:http://phx.corporate-ir.net/External.File?t=1&item=VHIwZT0yfFBhcmVudEIEPTUwODA3NDh8Q2hpbGRJRD01MzEyNjY=> [retrieved on 20150614] *
BUTLER ET AL.: "Antibiotics in the clinical pipeline in 2013", THE JOUMAL OF ANTIBIOTICS, vol. 66, 4 September 2013 (2013-09-04), pages 517 - 591 *
LYKE ET AL.: "Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta ( IL -1 beta), IL -6, IL -8, IL -10, Tumor Necrosis Factor Alpha, and IL -12(p70) in Malian Children with Severe Plasmodium falciparum Malaria and Matched Uncomplicated Malaria or Healthy Controls", INFECTION AND IMMUNITY, vol. 72, no. 10, October 2004 (2004-10-01), pages 5630 - 5637 *
NICOLETTI ET AL.: "Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b", CLINICAL EXPERIMENTAL IMMUNOLOGY, vol. 113, July 1998 (1998-07-01), pages 96 - 99 *
PATTERSON ET AL.: "Understanding the neuroinflammatory response following concussion to develop treatment strategies", FRONTIERS IN CELLULAR NEUROSCIENCE, vol. 6, 22 October 2012 (2012-10-22), pages 1 - 10 *
POSTHUMUS ET AL.: "Serum levels of matix metaaloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis", RHEUMATOLOGY, vol. 38, no. 11, November 1999 (1999-11-01), pages 1081 - 1087 *
REKAS ET AL.: "Malignant Glaucoma", INTECH, 3 March 2014 (2014-03-03), pages 421 - 438, XP055235674, Retrieved from the Internet <URL:http://cdn.intechopen.com/pdfs-wm/44164.pdf> [retrieved on 20150614] *
RICE ET AL.: "Manual Physical Therapy for Non-Surgical Treatment of Adhesion-Related Small Bowel Obstructions: Two Case Reports", JOUMAL OF CLINICAL MEDICINE, vol. 2, 4 February 2013 (2013-02-04), pages 1 - 12, XP055235671 *
WONG ET AL.: "Epidemiology of Cytokines The Women On the Move through Activity and Nutrition (WOMAN) Study", AMERICAN JOURNAL OF EPIDEMIOLOGY, vol. 168, no. 04, 25 June 2008 (2008-06-25), pages 443 - 453 *

Also Published As

Publication number Publication date
WO2015153864A2 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
WO2015153864A3 (en) Methods for treating inflammatory conditions
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
EP3589192A4 (en) Universal device and method to integrate diagnostic testing into treatment in real-time
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
WO2017181079A3 (en) Methods for monitoring and treating cancer
EA201400491A1 (en) ACCOMPANYING DIAGNOSTICS FOR THERAPY WITH ANTIHIALURON AGENT AND METHODS
BR112013022493A2 (en) equipment and method for examining, diagnosing or assisting in the diagnosis and treatment of functional vision problems
BR112014018592A2 (en) composition and method for the diagnosis and treatment of diseases associated with neuronal degeneration
MX2017006242A (en) Determination of glycosaminoglycan levels by mass spectrometry.
WO2013128293A3 (en) Methods, apparatuses and systems for diagnosis and treatment of mood disorders
WO2015164431A3 (en) Methods, processes, devices and kits for the measurement of post traumatic stress disorder microrna markers
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2014144777A3 (en) Lipids that increase insulin sensitivity and methods of using the same
WO2016117969A3 (en) Lighting treatment device using lesion image analysis, method for detecting lesion site through lesion image analysis for use therein, and computing device-readable recording media having same recorded therein
WO2015034886A3 (en) Wellness panel for companion animals
WO2016040891A3 (en) In vitro compositions comprising human sample and amyloid targeting agent
JOP20190025A1 (en) Methods and composition for the prediction of the activity of enzastaurin
WO2015148389A3 (en) Diagnosis of multiple sclerosis in human and animal subjects
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
MX2022010954A (en) Device for detecting misfolded proteins and methods of use therof.
WO2016168344A8 (en) Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
MX2017003513A (en) Hsp90-targeted inflammation and infection imaging and therapy.
WO2015038634A3 (en) Multiplex diagnostic assay for lyme disease and other tick-borne diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15773101

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15773101

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/04/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15773101

Country of ref document: EP

Kind code of ref document: A2